Abstract
Most of the current therapies against cancer, and also those against immune diseases or viral infections, consist of empirically designed combination strategies, combining a variety of therapeutic agents. Drug combinations are widely used because multiple drugs affect multiple targets and cell subpopulations. The primary aim is a mutual enhancement of the therapeutic effects, while other benefits may include decreased side effects and the delay or prevention of drug resistance. The large majority of combination regimens are being developed empirically and there are few experimental studies designed to explore thoroughly different drug combinations, using appropriate methods of analysis. However, the study of patterns of possible metabolic and biological interactions in preclinical models, as well as scheduling, should improve the development of most drug combinations. The definition of synergism is that the combination is more effective than each agent separately, e.g., one of the agents augments the actions of the second drug. The definition of antagonism is that the combination is less effective than the single agents, e.g. one of the agents counteracts the actions of the other. A combination can be studied by combining the two agents in various different ways, such as simultaneous or sequential combination schedules. It is essential to test the potency of a combination, before evaluation in the clinic, to prevent antagonistic actions. However, one should realize that an antagonistic action may be desired when toxicity is concerned, i.e. one drug decreases the side effects of another drug. Several attempts have been made to quantitatively measure the dose–effect relationship of each drug alone and its combinations and to determine whether a given combination would gain a synergistic effect. One of the most widely used ways to evaluate whether a combination is effective is the median-drug effect analysis method. Using this method, a combination index (CI) is calculated from drug cytotoxicity or growth inhibition curves. To calculate a CI, the computer software Calcusyn can be used, taking the entire shape of the growth inhibition curve into account for calculating whether a combination is synergistic, additive, or antagonistic. Here, we describe how combinations can be designed in vitro and how to analyze them using Calcusyn or Compusyn. Moreover, pitfalls, limitations, and advantages of using these combinations and Calcusyn/Compusyn are described.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Peters, G.J., van der Wilt, C.L., van Moorsel, C.J., Kroep, J.R., Bergman, A.M. and Ackland, S.P. (2000) Basis for effective combination cancer chemotherapy with antimetabolites. Pharmacol. Ther. 87, 227–53.
Keepers, Y.P., Pizao, P.E., Peters, G.J., van Ark-Otte, J., Winograd, B. and Pinedo, H.M. (1991) Comparison of the sulforhodamine B protein and tetrazolium (MTT) assays for in vitro chemosensitivity testing. Eur. J. Cancer. 27, 897–900.
Cree, I.A. and Kurbacher, C.M. (1999) ATP-based tumor chemosensitivity testing: assisting new agent development. Anticancer Drugs. 10, 431–5.
Berenbaum, M.C. (1989) What is synergy? (1989) Pharmacol. Rev. 41, 93–141.
Webb, J.L. (1963) Effect of more than one inhibitor. In Enzymes and Metabolic Inhibitors. New York: Academic Press. pp. 66–79.
Greco, W.R., Bravo, G., and Parsons, J.C. (1995) The search for synergy: a critical review from a response surface perspective. Pharmacol. Rev. 47, 331–385.
Kanzawa, F. and Saijo, N. (1997) In vitro interaction between gemcitabine and other anticancer drugs using a novel three-dimensional model. Semin. Oncol. 24, :S7-8-S7-16.
Chou, T.C. and Talalay, P. (1984) Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv. Enzyme Regul. 22, 27–55.
Chou, T.C. (2010) Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res. 70, 440–6.
Elion, G.B., Singer, S. and Hitchings G.H. (1954) Antagonists of nucleic acid derivatives: Part VIII. Synergism in combinations of biochemically related antimetabolites. J. Biol. Chem. 208, 477–488.
Steel, G.G. and Peckham, M.J. (1979) Exploitable mechanisms in combined radiotherapy-chemotherapy: the concept of additivity. Int. J. Radiat. Oncol. Biol. Phys. 5, 85–91.
Padrón, J.M., van Moorsel, C.J., Bergman, A.M., Smitskamp-Wilms, E., van der Wilt, C.L. and Peters, G.J. (1999) Selective cell kill of the combination of gemcitabine and cisplatin in multilayered postconfluent tumor cell cultures. Anticancer Drugs 10, 445–52.
Giovannetti, E., Lemos, C., Tekle, C., Smid, K., Nannizzi, S., Rodriguez, J.A., Ricciardi, S., Danesi, R., Giaccone, G. and Peters, G.J. (2008) Molecular mechanisms underlying the synergistic interaction of erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor, with the multitargeted antifolate pemetrexed in non-small-cell lung cancer cells. Mol. Pharmacol. 73, 1290–300.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2011 Springer Science+Business Media, LLC
About this protocol
Cite this protocol
Bijnsdorp, I.V., Giovannetti, E., Peters, G.J. (2011). Analysis of Drug Interactions. In: Cree, I. (eds) Cancer Cell Culture. Methods in Molecular Biology, vol 731. Humana Press. https://doi.org/10.1007/978-1-61779-080-5_34
Download citation
DOI: https://doi.org/10.1007/978-1-61779-080-5_34
Published:
Publisher Name: Humana Press
Print ISBN: 978-1-61779-079-9
Online ISBN: 978-1-61779-080-5
eBook Packages: Springer Protocols